

## CHAPTER V: REFERENCES

1. Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J. D., Coopersmith, C. M., Hotchkiss, R. S., Levy, M. M., Marshall, J. C., Martin, G. S., Opal, S. M., Rubenfeld, G. D., van der Poll, T., Vincent, J. L. & Angus, D. C. (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), *Jama*. **315**, 801-10.
2. Trivedi, V., Bavishi, C. & Jean, R. (2015) Impact of obesity on sepsis mortality: A systematic review, *Journal of critical care*. **30**, 518-24.
3. Hodgins, K. E. & Moss, M. (2008) The epidemiology of sepsis, *Current pharmaceutical design*. **14**, 1833-9.
4. Chatterjee, S., Bhattacharya, M. & Todi, S. K. (2017) Epidemiology of Adult-population Sepsis in India: A Single Center 5 Year Experience, *Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine*. **21**, 573-577.
5. Novosad, S. A., Sapiano, M. R., Grigg, C., Lake, J., Robyn, M., Dumyati, G., Felsen, C., Blog, D., Dufort, E., Zansky, S., Wiedeman, K., Avery, L., Dantes, R. B., Jernigan, J. A., Magill, S. S., Fiore, A. & Epstein, L. (2016) Vital Signs: Epidemiology of Sepsis: Prevalence of Health Care Factors and Opportunities for Prevention, *MMWR Morbidity and mortality weekly report*. **65**, 864-9.
6. Eshwara, V. K., Munim, F., Tellapragada, C., Kamath, A., Varma, M., Lewis, L. E. & Mukhopadhyay, C. (2013) Staphylococcus aureus bacteremia in an Indian tertiary care hospital: observational study on clinical epidemiology, resistance characteristics, and carriage of the Panton-Valentine leukocidin gene, *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. **17**, e1051-5.
7. Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J. L., Ramsay, G. & International Sepsis Definitions, C. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference, *Intensive care medicine*. **29**, 530-8.
8. Finfer, S. & Vincent, J. L. (2013) Critical care--an all-encompassing specialty, *The New England journal of medicine*. **369**, 669-70.
9. van der Poll, T. & Opal, S. M. (2008) Host-pathogen interactions in sepsis, *The Lancet Infectious Diseases*. **8**, 32-43.

10. Stearns-Kurosawa, D. J., Osuchowski, M. F., Valentine, C., Kurosawa, S. & Remick, D. G. (2011) The pathogenesis of sepsis, *Annual review of pathology*. **6**, 19-48.
11. Bochud, P. Y. & Calandra, T. (2003) Pathogenesis of sepsis: new concepts and implications for future treatment, *Bmj*. **326**, 262-6.
12. Sukhithasri, V., Nisha, N., Biswas, L., Anil Kumar, V. & Biswas, R. (2013) Innate immune recognition of microbial cell wall components and microbial strategies to evade such recognitions, *Microbiological research*. **168**, 396-406.
13. Chan, J. K., Roth, J., Oppenheim, J. J., Tracey, K. J., Vogl, T., Feldmann, M., Horwood, N. & Nanchahal, J. (2012) Alarmins: awaiting a clinical response, *The Journal of clinical investigation*. **122**, 2711-9.
14. Gauer, R. L. (2013) Early recognition and management of sepsis in adults: the first six hours, *American family physician*. **88**, 44-53.
15. Jung, S. W., Kim, D. H., Shin, S. J., Kang, B. Y., Eho, Y. J. & Yang, S. W. (2017) Septic arthritis associated with systemic sepsis, *International orthopaedics*.
16. Jenkins, P. J., Phillips, S. A., Gaston, P., Dave, J. & Breusch, S. J. (2010) Be vigilant for secondary periprosthetic joint infection, *The Practitioner*. **254**, 28-32, 3.
17. Tarkowski, A., Collins, L. V., Gjertsson, I., Hultgren, O. H., Jonsson, I.-M., Sakiniene, E. & Verdrengh, M. (2001) Model systems: Modeling human staphylococcal arthritis and sepsis in the mouse, *Trends in Microbiology*. **9**, 321-326.
18. Corrado, A., Donato, P., Maccari, S., Cecchi, R., Spadafina, T., Arcidiacono, L., Tavarini, S., Sammiceli, C., Laera, D., Manetti, A. G., Ruggiero, P., Galletti, B., Nuti, S., De Gregorio, E., Bertholet, S., Seubert, A., Bagnoli, F., Bensi, G. & Chiarot, E. (2016) *Staphylococcus aureus*-dependent septic arthritis in murine knee joints: local immune response and beneficial effects of vaccination, *Sci Rep*. **6**, 38043.
19. Lin, W. T., Wu, C. D., Cheng, S. C., Chiu, C. C., Tseng, C. C., Chan, H. T., Chen, P. Y. & Chao, C. M. (2015) High Prevalence of Methicillin-Resistant *Staphylococcus aureus* among Patients with Septic Arthritis Caused by *Staphylococcus aureus*, *PLoS one*. **10**, e0127150.
20. Ali, A., Zhu, X., Kwiecinski, J., Gjertsson, I., Lindholm, C., Iwakura, Y., Wang, X., Lycke, N., Josefsson, E., Pullerits, R. & Jin, T. (2015) Antibiotic-killed *Staphylococcus aureus* induces destructive arthritis in mice, *Arthritis Rheumatol*. **67**, 107-16.

21. Lesage, V., Van Pee, D., Luyx, C., Nachega, J. B., Boutsen, Y. & Swine, C. (1998) Septic arthritis caused by *Haemophilus influenzae* associated with endocarditis, *Clinical rheumatology*. **17**, 340-2.
22. Shirtliff, M. E. & Mader, J. T. (2002) Acute septic arthritis, *Clin Microbiol Rev*. **15**, 527-44.
23. Stevens, D. L., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J., Gorbach, S. L., Hirschmann, J. V., Kaplan, S. L., Montoya, J. G., Wade, J. C. & Infectious Diseases Society of, A. (2014) Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America, *Clin Infect Dis*. **59**, e10-52.
24. Barnabe, C., Jones, C. A., Bernatsky, S., Peschken, C. A., Voaklander, D., Homik, J., Crowshoe, L. F., Esdaile, J. M., El-Gabalawy, H. & Hemmelgarn, B. (2017) Inflammatory Arthritis Prevalence and Health Services Use in the First Nations and Non-First Nations Populations of Alberta, Canada, *Arthritis care & research*. **69**, 467-474.
25. Tande, A. J. & Patel, R. (2014) Prosthetic joint infection, *Clin Microbiol Rev*. **27**, 302-45.
26. Tarkowski, A., Bokarewa, M., Collins, L. V., Gjertsson, I., Hultgren, O. H., Jin, T., Jonsson, I. M., Josefsson, E., Sakiniene, E. & Verdrengh, M. (2002) Current status of pathogenetic mechanisms in staphylococcal arthritis, *FEMS microbiology letters*. **217**, 125-32.
27. Broy, S. B. & Schmid, F. R. (1986) A comparison of medical drainage (needle aspiration) and surgical drainage (arthrotomy or arthroscopy) in the initial treatment of infected joints, *Clinics in rheumatic diseases*. **12**, 501-22.
28. Broy, S. B., Stulberg, S. D. & Schmid, F. R. (1986) The role of arthroscopy in the diagnosis and management of the septic joint, *Clinics in rheumatic diseases*. **12**, 489-500.
29. Winn, W. C. & Koneman, E. W. (2006) *Koneman's Color Atlas and Textbook of Diagnostic Microbiology*, Lippincott Williams & Wilkins.
30. Kim, H. K., Alman, B. & Cole, W. G. (2000) A shortened course of parenteral antibiotic therapy in the management of acute septic arthritis of the hip, *Journal of pediatric orthopedics*. **20**, 44-7.
31. Peltola, H., Paakkonen, M., Kallio, P. & Kallio, M. J. (2009) What is the appropriate treatment course for bacterial arthritis in children? Reply to Bradley, *Clin Infect Dis*. **49**, 993.

32. Brown, A. F., Leech, J. M., Rogers, T. R. & McLoughlin, R. M. (2014) Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design, *Frontiers in immunology*. **4**, 507.
33. Freeman, R., Hudson, S. J. & Burdess, D. (1990) Crystal violet reactions of fresh clinical isolates of Staphylococcus aureus from two British hospitals, *Epidemiology and infection*. **105**, 493-500.
34. Janda, W. M., Ristow, K. & Novak, D. (1994) Evaluation of RapiDEC Staph for identification of Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus saprophyticus, *Journal of clinical microbiology*. **32**, 2056-9.
35. Otto, M. (2010) Staphylococcus colonization of the skin and antimicrobial peptides, *Expert review of dermatology*. **5**, 183-195.
36. Chakraborty, S. P., Mahapatra, S. K. & Roy, S. (2011) Biochemical characters and antibiotic susceptibility of *Staphylococcus aureus* isolates, *Asian Pac J Trop Biomed*. **1**, 212-6.
37. Sperber, W. H. & Tatini, S. R. (1975) Interpretation of the tube coagulase test for identification of Staphylococcus aureus, *Appl Microbiol*. **29**, 502-5.
38. Colbeck, J. C. & Proom, H. (1944) Dried Rabbit Plasma for the Staphylococcus Coagulase Test, *Br Med J*. **2**, 471.
39. Yotis, W. W. & Ekstedt, R. D. (1959) Studies on staphylococci. I. Effect of serum and coagulase on the metabolism of coagulase positive and coagulase negative strains, *J Bacteriol*. **78**, 567-74.
40. Becker, K., Heilmann, C. & Peters, G. (2014) Coagulase-negative staphylococci, *Clin Microbiol Rev*. **27**, 870-926.
41. Otto, M. (2012) Molecular basis of *Staphylococcus epidermidis* infections, *Semin Immunopathol*. **34**, 201-14.
42. Kateete, D. P., Kimani, C. N., Katabazi, F. A., Okeng, A., Okee, M. S., Nanteza, A., Joloba, M. L. & Najjuka, F. C. (2010) Identification of *Staphylococcus aureus*: DNase and Mannitol salt agar improve the efficiency of the tube coagulase test, *Ann Clin Microbiol Antimicrob*. **9**, 23.
43. Schleifer, K. H. & Kloos, W. E. (1975) Isolation and Characterization of Staphylococci from Human Skin I. Amended Descriptions of *Staphylococcus epidermidis* and *Staphylococcus saprophyticus* and Descriptions of Three New Species: *Staphylococcus cohnii*, *Staphylococcus*

*haemolyticus*, and *Staphylococcus xylosus*, *International Journal of Systematic and Evolutionary Microbiology*. **25**, 50-61.

44. Kloos, W. E. & Schleifer, K. H. (1975) Isolation and Characterization of Staphylococci from Human Skin II. Descriptions of Four New Species: *Staphylococcus warneri*, *Staphylococcus capitis*, *Staphylococcus hominis*, and *Staphylococcus simulans*1, *International Journal of Systematic and Evolutionary Microbiology*. **25**, 62-79.

45. Ramachandran, G. (2014) Gram-positive and gram-negative bacterial toxins in sepsis: a brief review, *Virulence*. **5**, 213-8.

46. Alonzo, F., 3rd & Torres, V. J. (2013) Bacterial survival amidst an immune onslaught: the contribution of the *Staphylococcus aureus* leukotoxins, *PLoS Pathog.* **9**, e1003143.

47. Enright, M. C., Robinson, D. A., Randle, G., Feil, E. J., Grundmann, H. & Spratt, B. G. (2002) The evolutionary history of methicillin-resistant *Staphylococcus aureus* (MRSA), *Proc Natl Acad Sci U S A*. **99**, 7687-92.

48. Koyama, T., Yamada, M. & Matsushashi, M. (1977) Formation of regular packets of *Staphylococcus aureus* cells, *J Bacteriol.* **129**, 1518-23.

49. Steed, L. L., Costello, J., Lohia, S., Jones, T., Spannhake, E. W. & Nguyen, S. (2014) Reduction of nasal *Staphylococcus aureus* carriage in health care professionals by treatment with a nonantibiotic, alcohol-based nasal antiseptic, *Am J Infect Control.* **42**, 841-6.

50. Wertheim, H. F., Melles, D. C., Vos, M. C., van Leeuwen, W., van Belkum, A., Verbrugh, H. A. & Nouwen, J. L. (2005) The role of nasal carriage in *Staphylococcus aureus* infections, *Lancet Infect Dis.* **5**, 751-62.

51. Kluytmans, J., van Belkum, A. & Verbrugh, H. (1997) Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks, *Clin Microbiol Rev.* **10**, 505-20.

52. Steinberg, J. P., Clark, C. C. & Hackman, B. O. (1996) Nosocomial and community-acquired *Staphylococcus aureus* bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance, *Clin Infect Dis.* **23**, 255-9.

53. Saravolatz, L. D., Pohlod, D. J. & Arking, L. M. (1982) Community-acquired methicillin-resistant *Staphylococcus aureus* infections: a new source for nosocomial outbreaks, *Ann Intern Med.* **97**, 325-9.

54. Salmenlinna, S., Lyytikäinen, O. & Vuopio-Varkila, J. (2002) Community-acquired methicillin-resistant *Staphylococcus aureus*, Finland, *Emerg Infect Dis.* **8**, 602-7.
55. Romano, R., Lu, D. & Holtom, P. (2006) Outbreak of community-acquired methicillin-resistant *Staphylococcus aureus* skin infections among a collegiate football team, *J Athl Train.* **41**, 141-5.
56. DeLeo, F. R., Otto, M., Kreiswirth, B. N. & Chambers, H. F. (2010) Community-associated methicillin-resistant *Staphylococcus aureus*, *Lancet.* **375**, 1557-68.
57. McCaig, L. F. & Nawar, E. W. (2006) National Hospital Ambulatory Medical Care Survey: 2004 emergency department summary, *Adv Data*, 1-29.
58. McCaig, L. F., McDonald, L. C., Mandal, S. & Jernigan, D. B. (2006) *Staphylococcus aureus*-associated skin and soft tissue infections in ambulatory care, *Emerg Infect Dis.* **12**, 1715-23.
59. Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E., McDougal, L. K., Carey, R. B., Talan, D. A. & Group, E. M. I. N. S. (2006) Methicillin-resistant *S. aureus* infections among patients in the emergency department, *The New England journal of medicine.* **355**, 666-74.
60. Tong, S. Y., Davis, J. S., Eichenberger, E., Holland, T. L. & Fowler, V. G., Jr. (2015) *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management, *Clin Microbiol Rev.* **28**, 603-61.
61. Hidron, A. I., Kempker, R., Moanna, A. & Rimland, D. (2010) Methicillin-resistant *Staphylococcus aureus* in HIV-infected patients, *Infect Drug Resist.* **3**, 73-86.
62. Indian Network for Surveillance of Antimicrobial Resistance group, I. (2013) Methicillin resistant *Staphylococcus aureus* (MRSA) in India: prevalence & susceptibility pattern, *Indian J Med Res.* **137**, 363-9.
63. Shetty, V., Trumbull, K., Hegde, A., Shenoy, V., Prabhu, R., K, S., Palavecino, E. & Shetty, A. K. (2014) Prevalence of Community-Acquired Methicillin-Resistant *Staphylococcus aureus* Nasal Colonization Among Children, *J Clin Diagn Res.* **8**, DC12-5.
64. Sharff, K. A., Richards, E. P. & Townes, J. M. (2013) Clinical management of septic arthritis, *Curr Rheumatol Rep.* **15**, 332.
65. Krijnen, P., Kaandorp, C. J., Steyerberg, E. W., van Schaardenburg, D., Moens, H. J. & Habbema, J. D. (2001) Antibiotic prophylaxis for haematogenous bacterial arthritis in patients with joint disease: a cost effectiveness analysis, *Ann Rheum Dis.* **60**, 359-66.

66. Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., M, J. R., Talan, D. A., Chambers, H. F. & Infectious Diseases Society of, A. (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children, *Clin Infect Dis.* **52**, e18-55.
67. Sakoulas, G., Eliopoulos, G. M., Moellering, R. C., Jr., Wennersten, C., Venkataraman, L., Novick, R. P. & Gold, H. S. (2002) Accessory gene regulator (agr) locus in geographically diverse *Staphylococcus aureus* isolates with reduced susceptibility to vancomycin, *Antimicrob Agents Chemother.* **46**, 1492-502.
68. Kumar, V. A., Nair, N., Thachathodiyl, R., Nandakumar, A., Dinesh, K. R., Thatcher, E., Karim, S. & Biswas, R. (2013) Molecular Characterization of Methicillin-Resistant *Staphylococcus aureus* Causing Fatal Purulent Pericarditis, *J Lab Physicians.* **5**, 136-8.
69. Piriz Duran, S., Kayser, F. H. & Berger-Bachi, B. (1996) Impact of sar and agr on methicillin resistance in *Staphylococcus aureus*, *FEMS microbiology letters.* **141**, 255-60.
70. Chambers, H. F. & Deleo, F. R. (2009) Waves of resistance: *Staphylococcus aureus* in the antibiotic era, *Nat Rev Microbiol.* **7**, 629-41.
71. Lowy, F. D. (2003) Antimicrobial resistance: the example of *Staphylococcus aureus*, *The Journal of clinical investigation.* **111**, 1265-73.
72. Naber, C. K. (2009) *Staphylococcus aureus* bacteremia: epidemiology, pathophysiology, and management strategies, *Clin Infect Dis.* **48 Suppl 4**, S231-7.
73. Kallen, A. J., Patel, P. R. & O'Grady, N. P. (2010) Preventing catheter-related bloodstream infections outside the intensive care unit: expanding prevention to new settings, *Clin Infect Dis.* **51**, 335-41.
74. David, M. Z. & Daum, R. S. (2010) Community-associated methicillin-resistant *Staphylococcus aureus*: epidemiology and clinical consequences of an emerging epidemic, *Clin Microbiol Rev.* **23**, 616-87.
75. Haas, P. J., de Haas, C. J., Kleibeuker, W., Poppelier, M. J., van Kessel, K. P., Kruijtzter, J. A., Liskamp, R. M. & van Strijp, J. A. (2004) N-terminal residues of the chemotaxis inhibitory protein of *Staphylococcus aureus* are essential for blocking formylated peptide receptor but not C5a receptor, *Journal of immunology.* **173**, 5704-11.

76. Wiman, B. & Wallen, P. (1975) Amino-acid sequence of the cyanogen-bromide fragment from human plasminogen that forms the linkage between the plasmin chains, *European journal of biochemistry*. **58**, 539-47.
77. Strominger, J. L., Park, J. T. & Thompson, R. E. (1959) Composition of the cell wall of *Staphylococcus aureus*: its relation to the mechanism of action of penicillin, *J Biol Chem*. **234**, 3263-8.
78. Dmitriev, B. A., Toukach, F. V., Holst, O., Rietschel, E. T. & Ehlers, S. (2004) Tertiary structure of *Staphylococcus aureus* cell wall murein, *J Bacteriol*. **186**, 7141-8.
79. Bera, A., Herbert, S., Jakob, A., Vollmer, W. & Gotz, F. (2005) Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of *Staphylococcus aureus*, *Mol Microbiol*. **55**, 778-87.
80. Bera, A., Biswas, R., Herbert, S., Kulauzovic, E., Weidenmaier, C., Peschel, A. & Gotz, F. (2007) Influence of wall teichoic acid on lysozyme resistance in *Staphylococcus aureus*, *J Bacteriol*. **189**, 280-3.
81. Watts, A., Ke, D., Wang, Q., Pillay, A., Nicholson-Weller, A. & Lee, J. C. (2005) *Staphylococcus aureus* strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence, *Infect Immun*. **73**, 3502-11.
82. Park, S., Gerber, S. & Lee, J. C. (2014) Antibodies to *Staphylococcus aureus* serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates, *Infect Immun*. **82**, 5049-55.
83. Lee, J. C., Park, J. S., Shepherd, S. E., Carey, V. & Fattom, A. (1997) Protective efficacy of antibodies to the *Staphylococcus aureus* type 5 capsular polysaccharide in a modified model of endocarditis in rats, *Infect Immun*. **65**, 4146-51.
84. Vollmer, W., Blanot, D. & de Pedro, M. A. (2008) Peptidoglycan structure and architecture, *FEMS Microbiol Rev*. **32**, 149-67.
85. Gust, A. A., Biswas, R., Lenz, H. D., Rauhut, T., Ranf, S., Kemmerling, B., Gotz, F., Glawischnig, E., Lee, J., Felix, G. & Nurnberger, T. (2007) Bacteria-derived peptidoglycans constitute pathogen-associated molecular patterns triggering innate immunity in Arabidopsis, *J Biol Chem*. **282**, 32338-48.
86. Liu, Z. Q., Deng, G. M., Foster, S. & Tarkowski, A. (2001) Staphylococcal peptidoglycans induce arthritis, *Arthritis Res*. **3**, 375-80.



87. Neuhaus, F. C. & Baddiley, J. (2003) A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in gram-positive bacteria, *Microbiology and molecular biology reviews : MMBR.* **67**, 686-723.
88. Swoboda, J. G., Campbell, J., Meredith, T. C. & Walker, S. (2010) Wall teichoic acid function, biosynthesis, and inhibition, *Chembiochem : a European journal of chemical biology.* **11**, 35-45.
89. Weidenmaier, C. & Peschel, A. (2008) Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions, *Nat Rev Microbiol.* **6**, 276-87.
90. Collins, L. V., Kristian, S. A., Weidenmaier, C., Faigle, M., Van Kessel, K. P., Van Strijp, J. A., Gotz, F., Neumeister, B. & Peschel, A. (2002) *Staphylococcus aureus* strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice, *J Infect Dis.* **186**, 214-9.
91. Vollmer, W. (2008) Structural variation in the glycan strands of bacterial peptidoglycan, *FEMS Microbiol Rev.* **32**, 287-306.
92. Kuipers, A., Stapels, D. A., Weerwind, L. T., Ko, Y. P., Ruyken, M., Lee, J. C., van Kessel, K. P. & Rooijackers, S. H. (2016) The *Staphylococcus aureus* polysaccharide capsule and Efb-dependent fibrinogen shield act in concert to protect against phagocytosis, *Microbiology.* **162**, 1185-94.
93. Das, D. & Bishayi, B. (2010) Contribution of Catalase and Superoxide Dismutase to the Intracellular Survival of Clinical Isolates of *Staphylococcus aureus* in Murine Macrophages, *Indian journal of microbiology.* **50**, 375-84.
94. Gaupp, R., Ledala, N. & Somerville, G. A. (2012) Staphylococcal response to oxidative stress, *Frontiers in cellular and infection microbiology.* **2**, 33.
95. Joo, H. S. & Otto, M. (2015) Mechanisms of resistance to antimicrobial peptides in staphylococci, *Biochimica et biophysica acta.* **1848**, 3055-61.
96. Gresham, H. D., Lowrance, J. H., Caver, T. E., Wilson, B. S., Cheung, A. L. & Lindberg, F. P. (2000) Survival of *Staphylococcus aureus* inside neutrophils contributes to infection, *Journal of immunology.* **164**, 3713-22.
97. Jevon, M., Guo, C., Ma, B., Mordan, N., Nair, S. P., Harris, M., Henderson, B., Bentley, G. & Meghji, S. (1999) Mechanisms of internalization of *Staphylococcus aureus* by cultured human osteoblasts, *Infect Immun.* **67**, 2677-81.

98. Kintarak, S., Whawell, S. A., Speight, P. M., Packer, S. & Nair, S. P. (2004) Internalization of *Staphylococcus aureus* by human keratinocytes, *Infect Immun.* **72**, 5668-75.
99. Rollin, G., Tan, X., Tros, F., Dupuis, M., Nassif, X., Charbit, A. & Coureuil, M. (2017) Intracellular Survival of *Staphylococcus aureus* in Endothelial Cells: A Matter of Growth or Persistence, *Frontiers in microbiology.* **8**, 1354.
100. Pushkaran, A. C., Nataraj, N., Nair, N., Gotz, F., Biswas, R. & Mohan, C. G. (2015) Understanding the Structure-Function Relationship of Lysozyme Resistance in *Staphylococcus aureus* by Peptidoglycan O-Acetylation Using Molecular Docking, Dynamics, and Lysis Assay, *Journal of chemical information and modeling.* **55**, 760-70.
101. Blake, C. C., Koenig, D. F., Mair, G. A., North, A. C., Phillips, D. C. & Sarma, V. R. (1965) Structure of hen egg-white lysozyme. A three-dimensional Fourier synthesis at 2 Angstrom resolution, *Nature.* **206**, 757-61.
102. Torsteinsdottir, I., Hakansson, L., Hallgren, R., Gudbjornsson, B., Arvidson, N. G. & Venge, P. (1999) Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis, *Rheumatology.* **38**, 1249-54.
103. Klockars, M. & Pettersson, T. (1985) Lysozyme concentrations in synovial fluid, pleural fluid and thoracic duct lymph in rheumatoid arthritis, *Scandinavian journal of rheumatology.* **14**, 69-75.
104. Perera, S., Sabin, E., Nelson, P. & Lowe, D. (1998) Increases in salivary lysozyme and IgA concentrations and secretory rates independent of salivary flow rates following viewing of humorous videotape, *International journal of behavioral medicine.* **5**, 118-28.
105. Saari, K. M., Aine, E., Posz, A. & Klockars, M. (1983) Lysozyme content of tears in normal subjects and in patients with external eye infections, *Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie.* **221**, 86-8.
106. Shimada, T., Park, B. G., Wolf, A. J., Brikos, C., Goodridge, H. S., Becker, C. A., Reyes, C. N., Miao, E. A., Aderem, A., Gotz, F., Liu, G. Y. & Underhill, D. M. (2010) *Staphylococcus aureus* evades lysozyme-based peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1beta secretion, *Cell Host Microbe.* **7**, 38-49.

107. Crisostomo, M. I., Vollmer, W., Kharat, A. S., Inhulsen, S., Gehre, F., Buckenmaier, S. & Tomasz, A. (2006) Attenuation of penicillin resistance in a peptidoglycan O-acetyl transferase mutant of *Streptococcus pneumoniae*, *Mol Microbiol.* **61**, 1497-509.
108. Rae, C. S., Geissler, A., Adamson, P. C. & Portnoy, D. A. (2011) Mutations of the *Listeria monocytogenes* peptidoglycan N-deacetylase and O-acetylase result in enhanced lysozyme sensitivity, bacteriolysis, and hyperinduction of innate immune pathways, *Infect Immun.* **79**, 3596-606.
109. Aubry, C., Goulard, C., Nahori, M. A., Cayet, N., Decalf, J., Sachse, M., Boneca, I. G., Cossart, P. & Dussurget, O. (2011) OatA, a peptidoglycan O-acetyltransferase involved in *Listeria monocytogenes* immune escape, is critical for virulence, *J Infect Dis.* **204**, 731-40.
110. Rosenthal, R. S., Folkening, W. J., Miller, D. R. & Swim, S. C. (1983) Resistance of O-acetylated gonococcal peptidoglycan to human peptidoglycan-degrading enzymes, *Infect Immun.* **40**, 903-11.
111. Swim, S. C., Gfell, M. A., Wilde, C. E., 3rd & Rosenthal, R. S. (1983) Strain distribution in extents of lysozyme resistance and O-acetylation of gonococcal peptidoglycan determined by high-performance liquid chromatography, *Infect Immun.* **42**, 446-52.
112. Clarke, A. J. & Dupont, C. (1992) O-acetylated peptidoglycan: its occurrence, pathobiological significance, and biosynthesis, *Canadian journal of microbiology.* **38**, 85-91.
113. Brumfitt, W. (1959) The mechanism of development of resistance to lysozyme by some gram-positive bacteria and its results, *British journal of experimental pathology.* **40**, 441-51.
114. Needham, A. J., Kibart, M., Crossley, H., Ingham, P. W. & Foster, S. J. (2004) *Drosophila melanogaster* as a model host for *Staphylococcus aureus* infection, *Microbiology.* **150**, 2347-55.
115. Sifri, C. D., Begun, J., Ausubel, F. M. & Calderwood, S. B. (2003) *Caenorhabditis elegans* as a model host for *Staphylococcus aureus* pathogenesis, *Infect Immun.* **71**, 2208-17.
116. Kaito, C., Akimitsu, N., Watanabe, H. & Sekimizu, K. (2002) Silkworm larvae as an animal model of bacterial infection pathogenic to humans, *Microbial pathogenesis.* **32**, 183-90.
117. Apidianakis, Y. & Rahme, L. G. (2009) *Drosophila melanogaster* as a model host for studying *Pseudomonas aeruginosa* infection, *Nature protocols.* **4**, 1285-94.
118. Sibley, C. D., Duan, K., Fischer, C., Parkins, M. D., Storey, D. G., Rabin, H. R. & Surette, M. G. (2008) Discerning the complexity of community interactions using a *Drosophila* model of polymicrobial infections, *PLoS Pathog.* **4**, e1000184.

119. Nimal, T. R., Baranwal, G., Bavya, M. C., Biswas, R. & Jayakumar, R. (2016) Anti-staphylococcal Activity of Injectable Nano Tigecycline/Chitosan-PRP Composite Hydrogel Using *Drosophila melanogaster* Model for Infectious Wounds, *ACS applied materials & interfaces*. **8**, 22074-83.
120. Nair, S. V., Baranwal, G., Chatterjee, M., Sachu, A., Vasudevan, A. K., Bose, C., Banerji, A. & Biswas, R. (2016) Antimicrobial activity of plumbagin, a naturally occurring naphthoquinone from *Plumbago rosea*, against *Staphylococcus aureus* and *Candida albicans*, *International journal of medical microbiology : IJMM*. **306**, 237-48.
121. Daum, R. S., Davis, W. H., Farris, K. B., Campeau, R. J., Mulvihill, D. M. & Shane, S. M. (1990) A model of *Staphylococcus aureus* bacteremia, septic arthritis, and osteomyelitis in chickens, *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. **8**, 804-13.
122. Zhang, F., Jun, M., Ledue, O., Herd, M., Malley, R. & Lu, Y. J. (2017) Antibody-mediated protection against *Staphylococcus aureus* dermonecrosis and sepsis by a whole cell vaccine, *Vaccine*. **35**, 3834-3843.
123. Qin, L., Da, F., Fisher, E. L., Tan, D. C., Nguyen, T. H., Fu, C. L., Tan, V. Y., McCausland, J. W., Sturdevant, D. E., Joo, H. S., Queck, S. Y., Cheung, G. Y. & Otto, M. (2017) Toxin Mediates Sepsis Caused by Methicillin-Resistant *Staphylococcus epidermidis*, *PLoS Pathog*. **13**, e1006153.
124. Mohammad, M., Na, M., Welin, A., Svensson, M. N., Ali, A., Jin, T. & Pullerits, R. (2016) RAGE Deficiency Impairs Bacterial Clearance in Murine Staphylococcal Sepsis, but Has No Significant Impact on Staphylococcal Septic Arthritis, *PloS one*. **11**, e0167287.
125. Duthie, E. S. & Lorenz, L. L. (1952) Staphylococcal coagulase; mode of action and antigenicity, *J Gen Microbiol*. **6**, 95-107.
126. Schlag, M., Biswas, R., Krismer, B., Kohler, T., Zoll, S., Yu, W., Schwarz, H., Peschel, A. & Gotz, F. (2010) Role of staphylococcal wall teichoic acid in targeting the major autolysin Atl, *Mol Microbiol*. **75**, 864-73.
127. Kuroda, M., Ohta, T., Uchiyama, I., Baba, T., Yuzawa, H., Kobayashi, I., Cui, L., Oguchi, A., Aoki, K., Nagai, Y., Lian, J., Ito, T., Kanamori, M., Matsumaru, H., Maruyama, A., Murakami, H., Hosoyama, A., Mizutani-Ui, Y., Takahashi, N. K., Sawano, T., Inoue, R., Kaito, C., Sekimizu, K., Hirakawa, H., Kuhara, S., Goto, S., Yabuzaki, J., Kanehisa, M., Yamashita, A.,

- Oshima, K., Furuya, K., Yoshino, C., Shiba, T., Hattori, M., Ogasawara, N., Hayashi, H. & Hiramatsu, K. (2001) Whole genome sequencing of methicillin-resistant *Staphylococcus aureus*, *Lancet*. **357**, 1225-40.
128. Rosenstein, R., Nerz, C., Biswas, L., Resch, A., Raddatz, G., Schuster, S. C. & Gotz, F. (2009) Genome analysis of the meat starter culture bacterium *Staphylococcus carnosus* TM300, *Applied and environmental microbiology*. **75**, 811-22.
129. Bera, A., Biswas, R., Herbert, S. & Gotz, F. (2006) The presence of peptidoglycan O-acetyltransferase in various staphylococcal species correlates with lysozyme resistance and pathogenicity, *Infect Immun*. **74**, 4598-604.
130. van der Maten, E., de Jonge, M. I., de Groot, R., van der Flier, M. & Langereis, J. D. (2017) A versatile assay to determine bacterial and host factors contributing to opsonophagocytotic killing in hirudin-anticoagulated whole blood, *Sci Rep*. **7**, 42137.
131. Kubica, M., Guzik, K., Koziel, J., Zarebski, M., Richter, W., Gajkowska, B., Golda, A., Maciag-Gudowska, A., Brix, K., Shaw, L., Foster, T. & Potempa, J. (2008) A potential new pathway for *Staphylococcus aureus* dissemination: the silent survival of *S. aureus* phagocytosed by human monocyte-derived macrophages, *PloS one*. **3**, e1409.
132. Kaynar, A. M., Bakalov, V., Laverde, S. M., Cambriel, A. I., Lee, B. H., Towheed, A., Gregory, A. D., Webb, S. A., Palladino, M. J., Bozza, F. A., Shapiro, S. D. & Angus, D. C. (2016) Cost of surviving sepsis: a novel model of recovery from sepsis in *Drosophila melanogaster*, *Intensive care medicine experimental*. **4**, 4.
133. Stranger-Jones, Y. K., Bae, T. & Schneewind, O. (2006) Vaccine assembly from surface proteins of *Staphylococcus aureus*, *Proc Natl Acad Sci U S A*. **103**, 16942-7.
134. Bremell, T., Lange, S., Yacoub, A., Ryden, C. & Tarkowski, A. (1991) Experimental *Staphylococcus aureus* arthritis in mice, *Infect Immun*. **59**, 2615-23.
135. Ali, A., Welin, A., Schwarze, J. C., Svensson, M. N., Na, M., Jarneborn, A., Magnusson, M., Mohammad, M., Kwiecinski, J., Josefsson, E., Bylund, J., Pullerits, R. & Jin, T. (2015) CTLA4 Immunoglobulin but Not Anti-Tumor Necrosis Factor Therapy Promotes Staphylococcal Septic Arthritis in Mice, *J Infect Dis*. **212**, 1308-16.
136. Fei, Y., Wang, W., Kwiecinski, J., Josefsson, E., Pullerits, R., Jonsson, I. M., Magnusson, M. & Jin, T. (2011) The combination of a tumor necrosis factor inhibitor and antibiotic alleviates staphylococcal arthritis and sepsis in mice, *J Infect Dis*. **204**, 348-57.

137. Fatima, F., Fei, Y., Ali, A., Mohammad, M., Erlandsson, M. C., Bokarewa, M. I., Nawaz, M., Valadi, H., Na, M. & Jin, T. (2017) Radiological features of experimental staphylococcal septic arthritis by micro computed tomography scan, *PloS one*. **12**, e0171222.
138. Sakurai, A., Okahashi, N., Nakagawa, I., Kawabata, S., Amano, A., Ooshima, T. & Hamada, S. (2003) Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand, *Infect Immun*. **71**, 6019-26.
139. Blaho, V. A., Zhang, Y., Hughes-Hanks, J. M. & Brown, C. R. (2011) 5-Lipoxygenase-deficient mice infected with *Borrelia burgdorferi* develop persistent arthritis, *Journal of immunology*. **186**, 3076-84.
140. Karimi, M., Biazar, E., Keshel, S. H., Ronaghi, A., Doostmohamadpour, J., Janfada, A. & Montazeri, A. (2014) Rat sciatic nerve reconstruction across a 30 mm defect bridged by an oriented porous PHBV tube with Schwann cell as artificial nerve graft, *ASAIO J*. **60**, 224-33.
141. Shankarappa, S. A., Sagie, I., Tsui, J. H., Chiang, H. H., Stefanescu, C., Zurakowski, D. & Kohane, D. S. (2012) Duration and local toxicity of sciatic nerve blockade with coinjected site 1 sodium-channel blockers and quaternary lidocaine derivatives, *Reg Anesth Pain Med*. **37**, 483-9.
142. Eilam, D. (2003) Open-field behavior withstands drastic changes in arena size, *Behav Brain Res*. **142**, 53-62.
143. Kim, S., Lee, S., Ryu, S., Suk, J. & Park, C. (2002) Comparative analysis of the anxiety-related behaviors in four inbred mice, *Behav Processes*. **60**, 181-190.
144. Brand, D. D., Latham, K. A. & Rosloniec, E. F. (2007) Collagen-induced arthritis, *Nature protocols*. **2**, 1269-75.
145. Zhao, Y. X., Nilsson, I. M. & Tarkowski, A. (1998) The dual role of interferon-gamma in experimental *Staphylococcus aureus* septicaemia versus arthritis, *Immunology*. **93**, 80-5.
146. Gjertsson, I., Jonsson, I. M., Peschel, A., Tarkowski, A. & Lindholm, C. (2011) Formylated peptides are important virulence factors in *Staphylococcus aureus* arthritis in mice, *J Infect Dis*. **205**, 305-11.
147. Jonsson, I. M., Mazmanian, S. K., Schneewind, O., Verdrengh, M., Bremell, T. & Tarkowski, A. (2002) On the role of *Staphylococcus aureus* sortase and sortase-catalyzed surface protein anchoring in murine septic arthritis, *J Infect Dis*. **185**, 1417-24.

148. Nair, N., Vinod, V., Suresh, M. K., Vijayrajratnam, S., Biswas, L., Peethambaran, R., Vasudevan, A. K. & Biswas, R. (2015) Amidase, a cell wall hydrolase, elicits protective immunity against *Staphylococcus aureus* and *S. epidermidis*, *Int J Biol Macromol.* **77**, 314-21.
149. Kamekura, S., Hoshi, K., Shimoaka, T., Chung, U., Chikuda, H., Yamada, T., Uchida, M., Ogata, N., Seichi, A., Nakamura, K. & Kawaguchi, H. (2005) Osteoarthritis development in novel experimental mouse models induced by knee joint instability, *Osteoarthritis Cartilage.* **13**, 632-41.
150. Waung, J. A., Maynard, S. A., Gopal, S., Gogakos, A., Logan, J. G., Williams, G. R. & Bassett, J. H. (2014) Quantitative X-ray microradiography for high-throughput phenotyping of osteoarthritis in mice, *Osteoarthritis Cartilage.* **22**, 1396-400.
151. Rioja, I., Bush, K. A., Buckton, J. B., Dickson, M. C. & Life, P. F. (2004) Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment, *Clin Exp Immunol.* **137**, 65-73.
152. Melnikov, V. Y., Faubel, S., Siegmund, B., Lucia, M. S., Ljubanovic, D. & Edelstein, C. L. (2002) Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice, *The Journal of clinical investigation.* **110**, 1083-91.
153. Baranwal, G., Mohammad, M., Jarneborn, A., Reddy, B. R., Golla, A., Chakravarty, S., Biswas, L., Gotz, F., Shankarappa, S., Jin, T. & Biswas, R. (2017) Impact of cell wall peptidoglycan O-acetylation on the pathogenesis of *Staphylococcus aureus* in septic arthritis, *International journal of medical microbiology : IJMM.* **307**, 388-397.
154. Goldenberg, D. L. (1998) Septic arthritis, *Lancet.* **351**, 197-202.
155. Verdrengh, M. & Tarkowski, A. (1997) Role of neutrophils in experimental septicemia and septic arthritis induced by *Staphylococcus aureus*, *Infect Immun.* **65**, 2517-21.
156. Na, M., Jarneborn, A., Ali, A., Welin, A., Magnusson, M., Stokowska, A., Pekna, M. & Jin, T. (2016) Deficiency of the Complement Component 3 but Not Factor B Aggravates *Staphylococcus aureus* Septic Arthritis in Mice, *Infect Immun.* **84**, 930-9.
157. Verdrengh, M., Kum, W., Chow, A. & Tarkowski, A. (1999) The effect of site-specific monoclonal antibodies directed to toxic shock syndrome toxin-1 in experimental *Staphylococcus aureus* arthritis, *Clin Exp Immunol.* **118**, 268-70.

158. Abdelnour, A., Bremell, T., Holmdahl, R. & Tarkowski, A. (1994) Clonal expansion of T lymphocytes causes arthritis and mortality in mice infected with toxic shock syndrome toxin-1-producing *staphylococci*, *Eur J Immunol.* **24**, 1161-6.

159. Peschel, A., Jack, R. W., Otto, M., Collins, L. V., Staubitz, P., Nicholson, G., Kalbacher, H., Nieuwenhuizen, W. F., Jung, G., Tarkowski, A., van Kessel, K. P. & van Strijp, J. A. (2001) *Staphylococcus aureus* resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine, *J Exp Med.* **193**, 1067-76.